Aisling Capital Management LP Buys Sunesis Pharmaceuticals Inc, Aeglea BioTherapeutics Inc, Sells Arcus Biosciences Inc

May 20, 2019

Investment company Aisling Capital Management LP buys Sunesis Pharmaceuticals Inc, Aeglea BioTherapeutics Inc, sells Arcus Biosciences Inc during the 3-months ended 2019Q1, according to the most recent filings of the investment company, Aisling Capital Management LP. As of 2019Q1, Aisling Capital Management LP owns 12 stocks with a total value of $131 million. These are the details of the buys and sells.

Added Positions: SNSS, AGLE, AVRO,
Reduced Positions: RCUS,

For the details of Aisling Capital Management LP's stock buys and sells, go to https://www.gurufocus.com/guru/aisling+capital+management+lp/current-portfolio/portfolio

These are the top 5 holdings of Aisling Capital Management LP

Eidos Therapeutics Inc (EIDX) - 1,123,630 shares, 20.07% of the total portfolio.
Avrobio Inc (AVRO) - 811,998 shares, 13.64% of the total portfolio. Shares added by 10.18%
ObsEva SA (OBSV) - 1,386,338 shares, 13.51% of the total portfolio.
Biohaven Pharmaceutical Holding Co Ltd (BHVN) - 274,513 shares, 10.76% of the total portfolio.
Marker Therapeutics Inc (GX1N) - 2,000,000 shares, 10.06% of the total portfolio.

Added: Sunesis Pharmaceuticals Inc (SNSS)

Aisling Capital Management LP added to a holding in Sunesis Pharmaceuticals Inc by 192.31%. The purchase prices were between $0.42 and $1.28, with an estimated average price of $0.64. The stock is now traded at around $1.14. The impact to a portfolio due to this purchase was 4.63%. The holding were 7,600,000 shares as of .

Added: Aeglea BioTherapeutics Inc (AGLE)

Aisling Capital Management LP added to a holding in Aeglea BioTherapeutics Inc by 40.56%. The purchase prices were between $7.49 and $9.4, with an estimated average price of $8.33. The stock is now traded at around $6.50. The impact to a portfolio due to this purchase was 2.16%. The holding were 1,220,911 shares as of .

Reduced: Arcus Biosciences Inc (RCUS)

Aisling Capital Management LP reduced to a holding in Arcus Biosciences Inc by 37.87%. The sale prices were between $8.95 and $12.49, with an estimated average price of $10.86. The stock is now traded at around $9.64. The impact to a portfolio due to this sale was -2.31%. Aisling Capital Management LP still held 333,333 shares as of .

Here is the complete portfolio of Aisling Capital Management LP. Also check out:

1. Aisling Capital Management LP's Undervalued Stocks
2. Aisling Capital Management LP's Top Growth Companies, and
3. Aisling Capital Management LP's High Yield stocks
4. Stocks that Aisling Capital Management LP keeps buying

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.